All In Biotech

Drug Trial Radar · NCT00790751

Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED

A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Avanafil (TA-1790) in Subjects With Generalized Erectile Dysfunction

Last checked: Nov 20, 2026Latest source record: Jul 11, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 646 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

646

Actual

Start

Nov 2008

Primary completion

Aug 2009

Study completion Aug 2009

Sponsor

Lead sponsor
VIVUS LLCIndustry
Sponsor type
Industry
First posted
Nov 13, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to compare the safety and efficacy of 3 doses of avanafil to placebo in men with mild to severe erectile dysfunction.

Conditions

  • Erectile Dysfunction

Interventions

  • placeboDrug

    30 minutes orally prior to initiation of sexual activity

  • avanafilDrug

    30 minutes orally prior to initiation of sexual activity

  • avanafilDrug

    30 minutes orally prior to initiation of sexual activity

  • avanafilDrug

    30 minutes orally prior to initiation of sexual activity

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Percentage of Sexual Attempts in Which Subjects Were Able to Maintain an Erection of Sufficient Duration to Have Successful IntercourseTime frame: Baseline, 12 weeks
  2. Change in Percentage of Sexual Attempts in Which Subjects Were Able to Insert the Penis Into the Partner's VaginaTime frame: Baseline, 12 weeks
  3. Change in International Index of Erectile Function - Erectile Function Domain (IIEF-EF) ScoreTime frame: Baseline, End of Treatment (up to 12 weeks)

Locations

41 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Homewood, Alabama

  • Research Site

    Tucson, Arizona

  • Research Site

    Sacramento, California

  • Research Site

    San Diego, California

  • Research Site

    San Diego, California

  • Research Site

    Waterbury, Connecticut

  • Research Site

    Clearwater, Florida

  • Research Site

    Clearwater, Florida

  • Research Site

    Coral Gables, Florida

  • Research Site

    Hialeah, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    Jupiter, Florida

  • Research Site

    Ocala, Florida

  • Research Site

    Pembroke Pines, Florida

  • Research Site

    Tampa, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Wichita, Kansas

  • Research Site

    Madisonville, Kentucky

  • Research Site

    Shreveport, Louisiana

  • Research Site

    Kansas City, Missouri

  • Research Site

    Lawrenceville, New Jersey

  • Research Site

    Albany, New York

  • Research Site

    New York, New York

  • Research Site

    Cary, North Carolina

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Charlotte, North Carolina

  • Research Site

    Harrisburg, North Carolina

  • Research Site

    Hickory, North Carolina

  • Research Site

    Raleigh, North Carolina

  • Research Site

    Salisbury, North Carolina

  • Research Site

    Wilmington, North Carolina

  • Research Site

    Winston-Salem, North Carolina

  • Research Site

    Beachwood, Ohio

  • Research Site

    Bala-Cynwyd, Pennsylvania

  • Research Site

    Lancaster, Pennsylvania

  • Research Site

    El Paso, Texas

  • Research Site

    Houston, Texas

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.